{"id":"02086119-3072-5126-b96c-ebf1d60a6ae0","stable_key":"d2e91bc7-8177-5ad3-ad9b-5d65813ce082:naringenin-human-pk","predicate":"produces_dose_related","statement":"Whole-orange extract supplying 150-900 mg naringenin produced dose-related serum exposure in 18 adults; half-life was about 2.65-3.0 hours at the fully profiled doses.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"e255da91-712c-5951-8dd0-8d7de05566da","mechanism_event_label":"Whole-orange extract supplying 150-900 mg naringenin produced dose-related serum exposure in 18 adults; half-life was about 2.65-3.0 hours at the fully profiled doses.","subject":{"id":"2a9350f6-01cc-5bea-8213-cd3ebb1b05cf","slug":"naringenin","display_name":"Naringenin","entity_type_key":"small_molecule"},"object":{"id":"8d133f69-d95e-5278-8ebe-d1bab95fa448","slug":"human-serum-total-naringenin","display_name":"Human serum naringenin after conjugate hydrolysis","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e255da91-712c-5951-8dd0-8d7de05566da","stable_key":"d2e91bc7-8177-5ad3-ad9b-5d65813ce082:naringenin-human-pk-event","event_type":"observed_relationship","label":"Whole-orange extract supplying 150-900 mg naringenin produced dose-related serum exposure in 18 adults; half-life was about 2.65-3.0 hours at the fully profiled doses.","description":"Whole-orange extract supplying 150-900 mg naringenin produced dose-related serum exposure in 18 adults; half-life was about 2.65-3.0 hours at the fully profiled doses.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"2a9350f6-01cc-5bea-8213-cd3ebb1b05cf","slug":"naringenin","display_name":"Naringenin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"8d133f69-d95e-5278-8ebe-d1bab95fa448","slug":"human-serum-total-naringenin","display_name":"Human serum naringenin after conjugate hydrolysis","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"150, 300, 600 or 900 mg naringenin in whole-orange extract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"24 hours with at least one-week washout","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Eighteen healthy adults in a randomized crossover trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The assay reported total released aglycone after hydrolysis and does not equal free circulating naringenin; this was a single-dose safety/PK trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Naringenin chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings.","comparator":null,"unit":null,"notes":"","entity":{"slug":"naringenin","display_name":"Naringenin","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Eighteen healthy adults in a randomized crossover trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Whole-orange extract supplying 150-900 mg naringenin produced dose-related serum exposure in 18 adults; half-life was about 2.65-3.0 hours at the fully profiled doses.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31468636/ DOI: 10.1111/dom.13868","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Serum LC-MS after beta-glucuronidase/sulfatase hydrolysis","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"25d984f8-524c-5be7-aeff-8bdcfa70fb8a","evidence_kind":"source_excerpt","locator":"Lines 11-20","start_line":11,"end_line":20,"excerpt":"## naringenin-human-pk\nWhole-orange extract supplying 150-900 mg naringenin produced dose-related serum exposure in 18 adults; half-life was about 2.65-3.0 hours at the fully profiled doses.\nModel/species: Eighteen healthy adults in a randomized crossover trial\nTissue/system: Serum LC-MS after beta-glucuronidase/sulfatase hydrolysis\nExposure: 150, 300, 600 or 900 mg naringenin in whole-orange extract\nRoute: Oral\nDuration: 24 hours with at least one-week washout\nLimits: The assay reported total released aglycone after hydrolysis and does not equal free circulating naringenin; this was a single-dose safety/PK trial.\nPrimary reference: Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31468636/ DOI: 10.1111/dom.13868\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"Eighteen healthy adults in a randomized crossover trial","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span with primary citation; not a publisher quotation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2804932d-46eb-5c43-8a45-0505e6b1ee05","stable_key":"import-d2e91bc7-8177-5ad3-ad9b-5d65813ce082","title":"Naringenin: mechanism of action and interactions (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text.","file_path":"","sha256":"e74776bf312a9ab53a4510c483e36e3093829e8c38725b9ae061e59e86f1145a","revision_id":"b96b5487-2b33-56ff-8955-9e8c0833533b","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}